Vertex chief earned $13.4M in '11

Former Vertex Pharmaceuticals ($VRTX) CEO Matthew Emmens left the chief executive position after reaping $13.4 million in total compensation last year, according to the Boston Business Journal. Despite the fact that Emmens was widely credited with ushering the biotech through a major transition--winning an approval on a game-changing new hepatitis C treatment--the earnings reflect a drop from the $14.9 million in compensation he received for 2010. Story